Humanwell Healthcare (Group) Co.,Ltd. (SHA:600079)

China flag China · Delayed Price · Currency is CNY
18.88
-0.33 (-1.72%)
Apr 30, 2026, 3:00 PM CST
Market Cap30.82B -10.9%
Revenue (ttm)23.96B -5.8%
Net Income1.86B +39.5%
EPS1.14 +39.0%
Shares Out1.63B
PE Ratio16.56
Forward PE12.54
Dividend0.48 (2.50%)
Ex-Dividend DateAug 19, 2025
Volume13,023,900
Average Volume10,092,769
Open19.10
Previous Close19.21
Day's Range18.84 - 19.11
52-Week Range16.73 - 23.66
Beta0.51
RSI52.35
Earnings DateApr 30, 2026

About SHA:600079

Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia; remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for patients who require opioid analgesia; nabuphine hydrochloride injection for use as an analgesic for anesthesia induction; alfentanil hydrochloride injec... [Read more]

Sector Healthcare
Founded 1988
Employees 17,153
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600079
Full Company Profile

Financial Performance

In 2025, SHA:600079's revenue was 23.96 billion, a decrease of -5.79% compared to the previous year's 25.44 billion. Earnings were 1.86 billion, an increase of 39.53%.

Financial Statements